Mizuho Maintains Outperform on Minimed Group, Raises Price Target to $28

Mizuho analyst Anthony Petrone has maintained an 'Outperform' rating on Minimed Group (NASDAQ: MMED) and raised the price target from $26 to $28. This adjustment reflects a positive outlook for the company's performance in the market.